• LAST PRICE
    1.5100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.4500/ 1
  • Ask / Lots
    1.8000/ 1
  • Open / Previous Close
    0.0000 / 1.5100
  • Day Range
    ---
  • 52 Week Range
    Low 1.1500
    High 2.9800
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.55
TimeVolumeARTL
09:32 ET81881.51
09:44 ET1201.5101
09:48 ET5391.615
09:50 ET11531.5201
10:11 ET9361.655
10:44 ET5001.59
11:36 ET1001.6145
02:45 ET24921.5401
03:01 ET13121.5512
03:03 ET5561.5345
03:14 ET9761.52
03:19 ET26001.52
03:35 ET28991.51
03:37 ET12001.52
03:51 ET1001.52
04:00 ET21081.51
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesARTL
Artelo Biosciences Inc
4.8M
-0.5x
---
United StatesBPTS
Biophytis SA
4.4M
-0.1x
---
United StatesPALI
Palisade Bio Inc
4.8M
-0.1x
---
United StatesGCTK
GlucoTrack Inc
4.9M
-0.7x
---
United StatesLIXT
Lixte Biotechnology Holdings Inc
5.0M
-0.7x
---
United StatesBTAX
Biostax Corp
5.1M
-3.2x
---
As of 2024-02-27

Company Information

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid agonist for the G protein-coupled receptor (GPCR) that targets a synthetic small molecule program, ART27.13, as a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder. In addition, the Company is also developing ART12.11 (CBD cocrystal), a solid-state composition of cannabidiol (CBD).

Contact Information

Headquarters
505 LOMAS SANTA FE, SUITE 160SOLANA BEACH, CA, United States 92075
Phone
858-925-7049
Fax
---

Executives

Independent Chairman of the Board
Connie Matsui
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Company Secretary, Director
Gregory Gorgas
Independent Director
Douglas Blayney
Independent Director
R. Martin Emanuele
Independent Director
Steven Kelly

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.8M
Revenue (TTM)
$0.00
Shares Outstanding
3.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.46
EPS
$-3.33
Book Value
$6.79
P/E Ratio
-0.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.